Subscribe to STAT+ and access exclusive benefits this month JOIN STAT+
Date: November 15–16, 2022 / Virtual
Location: Boston, MA
Be a part of two days of silo-breaking and solution-focused discussions on the most important topics in health care - from what's next for companies like Vertex and Pfizer to digital mental health care. Get your ticket to join the conversations with some of the industry's greatest minds. Subscribers receive a 20% discount on passes. Register
It’s not just Bitcoin. In the fiercely competitive world of health care, blockchain technology is quickly becoming the next frontier, offering hospitals, insurance companies, health tech startups and others in the industry the potential increase the protection of patient data, cut costs and create a stronger bulwark against fraud. Think of this report as your guide to health care’s big blockchain bet. Subscribers get 20% off all STAT Reports. Purchase
 STAT Trials Pulse is a clinical trials intelligence platform that combines machine learning and STAT’s newsroom to help you identify the signals and data points that matter most. Build watch lists to monitor the companies and therapeutic areas you care about, receive personalized email briefings about your followed trials, and decode patterns you wouldn’t otherwise see. Start your 30-day free trial today. No credit card needed. STAT+ Subscribers unlock 15% off an annual membership. Learn More
By Katie Palmer A familiar refrain echoes through drug ads in the United States. It’s heard at the end of TV spots and plastered across magazine pages: Ask your doctor if this drug is right for you. But as medicine moves increasingly online, direct-to-consumer advertising is adopting a more assertive catchphrase: Talk to a doctor now. For pharma companies, online prescribing has now become a powerful tool to drive sales, sending hundreds of thousands of patients to the clinic at the moment they’re most primed to ask for a specific prescription. Read more
STAT+ Reads The important stories you missed last month: Read more | 
No comments